Telomerase - 12 News by Pharmexa

Tip: You can further refine your news selection by departments and industries.

Telomerase - 12 News by Pharmexa

Tip: You can further refine your news selection by departments and industries.

Pharmexa enters into an agreement regarding GV1001 with the Korean company KAEL Co. Ltd

04-Nov-2008 - Pharmexa and KAEL Co. Ltd. of South Korea have entered into an agreement regarding GV1001 and Pharmexa´s Norwegian subsidiary Gemvax. Kael will acquire all shares of Gemvax and will thus assume all rights and responsibilities relating to the patent portfolio of GemVax including GV1001. In ...

telomerase milestone payments pancreatic cancer

New clinical results support telomerase vaccination in breast cancer

06-Nov-2007 - A group of prominent scientists from the Abramson Cancer Center and the University of Pennsylvania School of Medicine has published new clinical data on vaccination with the telomerase peptide I540 in 19 metastatic breast cancer patients. The results show that vaccination with the I540 ...

telomerase breast cancer T cells

Pharmexa again prevails against Geron in patent appeal

04-Sep-2007 - In May 2004 the US biotech company Geron filed an opposition against Pharmexa's issued European patent (EP1093381) covering the telomerase vaccine GV1001. In 2005, the Opposition Division of the European Patent Office refused to grant Geron's request for invalidation of the issued patent, but ...

telomerase Germany patents

Pharmexa starts pivotal phase III trial in the United States

07-May-2007 - The FDA has approved Pharmexas IND to start the PrimoVax trial in the United States. PrimoVax is a pivotal phase III trial testing the peptide vaccine GV1001 in patients with non-resectable pancreatic cancer. According to the plan the trial will enrol a total of 520 patients with pancreatic ...

telomerase Denmark orphan drugs

British doctors to start new phase III trial with Pharmexa's GV1001

19-Mar-2007 - A Phase III trial testing a new treatment for pancreatic cancer has now been initiated. Pharmexa has developed the drug and is co-financing the trial together with pharmaceuticals company Roche and Cancer Research UK. Referred to as the TeloVac trial, the recently initiated Phase III trial is a ...

telomerase chemotherapy education

Pharmexa receives patent in the United States and Europe on new vaccine candidate

12-Sep-2006 - Pharmexa has been granted a patent in the United States and has received communication of intent to grant from the European patent authorities on GV1003, a new peptide vaccine candidate aimed at the telomerase enzyme which is crucial to cancer cells' ability to divide. The telomerase enzyme, ...

telomerase amino acids mutations

Pharmexa receives approval of Phase II application with GV1001 in liver cancer

01-Sep-2006 - Pharmexa has received the necessary approvals in France regarding the Heptovax Phase II trial with GV1001 in liver cancer and will now initiate recruitment of patients. Approvals in Spain and Germany are expected within the next few weeks. The Heptovax trial is a Pase II trial evaluating the ...

telomerase cyclophosphamide Germany

Pharmexa prevails in opposition against Geron's European patent

19-Jun-2006 - Pharmexa has filed an opposition against the US biotech company Geron's European patent (EP841396) to the European Patent Office (EPO) and has requested an invalidation of three claims in the patent related to peptide vaccines against telomerase. In a decision on 13 June 2006, the European Patent ...

telomerase patents peptides

Pharmexa will start phase II trial in liver cancer with GV1001

02-Jun-2006 - Pharmexa has submitted the application to initiate the Heptovax phase II trial. The trial is planned to start in the third quarter of 2006 and will include up to 41 liver cancer patients. The Heptovax trial is a phase II, open-label trial evaluating the safety and efficacy of GV1001 in advanced ...

telomerase Germany hepatocellular carcinoma

Pharmexa receives US patent on the GV1001 vaccine for chemotherapy

26-Apr-2006 - The US patent authorities have issued a patent to Pharmexa on the GV1001 vaccine. GV1001 is Pharmexa's peptide vaccine targeting telomerase, which is currently under preparation for Phase III trials in pancreatic cancer. Pharmexa already has issued and validated patents for the GV1001 vaccine in ...

telomerase pancreatic cancer patents
Search all
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 27,211 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now